Peripheral blood stem cells

also known as Peripheral blood stem cell · PBSC

Developed for: myelodysplastic syndrome · acute myeloid leukemia · acute leukemia of ambiguous lineage · acute lymphoblastic leukemia · acute myocardial infarction · articular cartilage disorder · bone marrow failure syndrome · Burkitt lymphoma
+15 more
· chronic lymphocytic leukemia/small lymphocytic lymphoma · chronic myeloid leukemia · chronic myelomonocytic leukemia · Fanconi anemia · follicular lymphoma · HIV infectious disease · lymphoblastic lymphoma · lymphoplasmacytic lymphoma · mantle cell lymphoma · non-Hodgkin lymphoma · paroxysmal nocturnal hemoglobinuria · plasma cell leukemia · plasma cell myeloma · prolymphocytic leukemia · chronic granulomatous disease
Investigated by: Fred Hutchinson Cancer Center · Children's Hospital Medical Center, Cincinnati · DKMS · Kuala Lumpur Sports Medicine Centre · Masonic Cancer Center, University of Minnesota · Memorial Sloan Kettering Cancer Center
+5 more
· Ministry of Science, Technology and Innovation (MOSTI) Malaysia · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · Ribozyome · Seoul National University Hospital

Trials 9 · a red edge is where a trial was stopped

today NCT07046078 · Ph 2 NCT03970096 · Ph 2 NCT03520647 · Ph 2 NCT03275636 · Ph 2/3 NCT02661035 · Ph 2 NCT02143830 · Ph 2 NCT01076673 · Ph 2 NCT00501917 · Ph 2/3

2007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 27 trials
Phase 2	NCT07046078	Sep 2025 → Jun 2027 expected	acute leukemia of ambiguous lineage, chronic myelomonocytic leukemia, myelodysplastic syndrome	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT03970096	Nov 2019 → Dec 2027 expected	acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT03520647	Feb 2019 → Jun 2027 expected	myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	No outcome recorded
Phase 2	NCT02661035	Mar 2017 → Apr 2023	Burkitt lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +8	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT02143830	Apr 2014 → Dec 2026 expected	Fanconi anemia, acute myeloid leukemia, bone marrow failure syndrome, myelodysplastic syndrome	Children's Hospital Medical Center, Cincinnati	Recruiting	No outcome recorded
Phase 2	NCT01076673	Oct 2009 → May 2012	articular cartilage disorder	Kuala Lumpur Sports Medicine Centre	Completed	No outcome recorded
Phase 2	NCT00002221	—	HIV infectious disease, non-Hodgkin lymphoma	Ribozyome	Completed	No outcome recorded
Phase 2/32 trials
Phase 2/3	NCT03275636	Jan 2018 → Apr 2024	acute myeloid leukemia, myelodysplastic syndrome	DKMS	Completed	No outcome recorded
Phase 2/3	NCT00501917	Mar 2007 → Feb 2010	acute myocardial infarction	Seoul National University Hospital	Unknown	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/21 trial
Phase 1/2	NCT02629120 Comparator	Dec 2015 → Dec 2027 expected	chronic granulomatous disease	National Institute of Allergy and Infectious Diseases (NIAID)	Active not recruiting	No outcome recorded
Phase 31 trial
Phase 3	NCT01445821 Background	Sep 2011 → Jan 2017	systemic sclerosis	Northwestern University	Terminated	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

Field	Value	Cited text
Known as	Peripheral blood stem cells	“intracoronary infusion of peripheral blood stem cells mobilized with G-CSF” PMID 21299845 ↗ Feb 2011 7 “Peripheral Blood Stem Cells” NCT03520647 ↗ NCT02629120 ↗ NCT02661035 ↗ NCT00002221 ↗ NCT03275636 ↗ NCT01445821 ↗ NCT01076673 ↗
Known as	PBSC	“The purpose of this study was to compare histologic and magnetic resonance imaging (MRI) evaluation of articular cartilage regeneration in patients with chondral lesions...” NCT01076673 ↗
Known as	Peripheral blood stem cell	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02143830 ↗ 2 NCT03970096 ↗ NCT07046078 ↗
Action	Restore	“replace the patient's immune cells with functional immune cells” NCT02629120 ↗
Modality	Cell therapy	“the gene-modified and untreated stem cells are infused back into the patient” NCT00002221 ↗
Route	Intravenous	“The LN and L-TR/Tat-neo samples are pooled and given to the patient by IV infusion over about 15 minutes.” NCT00002221 ↗